Redhill Biopharma (STU:2RH) Gross Margin %: 0.00% (As of Dec. 2025)


STU:2RH Redhill Biopharma Ltd STU:2RH
18 GF Score
Price €8.24
! 6 Warning Signs
View Full Analysis

What is Redhill Biopharma Gross Margin %?

Redhill Biopharma STU:2RH 18 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 935 Drug Manufacturers companies, Redhill Biopharma ranks worse than 100% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. Redhill Biopharma's Gross Profit for the six months ended in Dec. 2025 was €-3.24 Mil. Redhill Biopharma's Revenue for the six months ended in Dec. 2025 was €-3.24 Mil. Therefore, Redhill Biopharma's Gross Margin % for the quarter that ended in Dec. 2025 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Redhill Biopharma's Gross Margin % or its related term are showing as below:

STU:2RH' s Gross Margin % Range Over the Past 10 Years
Min: -461.89   Med: 46.5   Max: 66.06
Current: -461.89


During the past 13 years, the highest Gross Margin % of Redhill Biopharma was 66.06%. The lowest was -461.89%. And the median was 46.50%.

STU:2RH's Gross Margin % is ranked worse than
100% of 935 companies
in the Drug Manufacturers industry
Industry Median: 48.54 vs STU:2RH: -461.89

Redhill Biopharma had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Redhill Biopharma was 0.00% per year.


Redhill Biopharma  (STU:2RH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Redhill Biopharma had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Redhill Biopharma Gross Margin % Related Terms


Redhill Biopharma Gross Margin % Historical Data

* Premium members only.

The historical data trend for Redhill Biopharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma Gross Margin % Chart

Redhill Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.39 46.06 0.00 0.00 0.00

Redhill Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 45.42 -143.20 60.61 0.00

STU:2RH vs SBFM, PRFX, CTTH: Gross Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma Gross Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Gross Margin % falls into.


STU:2RH
18GF Score
Redhill Biopharma Ltd STU:2RH
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redhill Biopharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Redhill Biopharma's Gross Margin for the fiscal year that ended in Dec. 2025 is calculated as

Gross Margin % (A: Dec. 2025 )=Gross Profit (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=0.2 / 0.244
=(Revenue - Cost of Goods Sold) / Revenue
=(0.244 - 0) / 0.244
=N/A %

Redhill Biopharma's Gross Margin for the quarter that ended in Dec. 2025 is calculated as


Gross Margin % (Q: Dec. 2025 )=Gross Profit (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-3.2 / -3.239
=(Revenue - Cost of Goods Sold) / Revenue
=(-3.239 - 0) / -3.239
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
Redhill Biopharma (STU:2RH) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Redhill Biopharma and its competitors. According to the industry distribution chart, Redhill Biopharma ranks #935 out of 935 companies in the Drug Manufacturers industry.
Is Redhill Biopharma's Gross Margin % too high?
Redhill Biopharma's current Gross Margin % is 0.00%. Based on the distribution chart, Redhill Biopharma ranks #935 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's Gross Margin % compare to SBFM and PRFX?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #935 out of 935 companies for Gross Margin %. This places Redhill Biopharma in the lower half of its industry. The industry median Gross Margin % is 48.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redhill Biopharma Business Description

Other Exchanges RDHL:USA
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score

Get the complete analysis for STU:2RH

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price